IHG plans cancel 1,000 bought-back shares

5 sourcesUpdated Aug 20, 2026

InterContinental Hotels Group PLC reported a share repurchase program activity in August 2026, with the company buying back 1,000 ordinary shares through Goldman Sachs International under the authority granted at the 8 May 2025 AGM, and plans to cancel the repurchased shares. The buyback on 17 August 2026 (and related reporting) saw prices ranging roughly from $158.50 to $160.15 per share, with an average around $159.41, reducing the number of shares in issue to about 148.56 million, excluding 5,431,782 held in treasury. In parallel filings, a chief human resources officer transaction disclosed that Tejas Katre disposed of 804 IHG shares on 14 August 2026 at about $158.90 per share, illustrating ongoing PDMR transparency requirements. Market coverage notes a generally neutral stance on IHG stock, with SparK and other analyses citing a solid operational backdrop and strong cash generation but flagging leverage and valuation considerations. The company’s filings and commentary collectively reflect ongoing capital-management activity aimed at returning value to shareholders while managing balance-sheet risk. Overall, investors are being kept informed about buyback progress, share-cancelation plans, and related executive-share transactions, all within the framework of IHG’s current market position.

In this story:

How it spread

Broke stocktitan.net · Aug 18, 6:00 AM5 sources +2d on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Coverage

stocktitan.netOtherInterContinental Hotels Group plans to cancel shares bought for up to $162 each

tipranks.comOtherInterContinental Hotels Discloses Share Sale by Human Resources Chief

Comments

Ask this story anything:

Free account · your comment posts right after signup

More on this story

Back to News

Photo: Fletcher / Wikimedia Commons (CC BY 4.0)

Health

Merck, Moderna Positive Phase 3 Melanoma Vaccine

Merck and Moderna reported positive Phase 3 results for their personalized mRNA cancer vaccine intismeran autogene (V940/mRNA-4157) added to Keytruda in high-risk, surgically treated melanoma, showing longer recurrence-free survival and reduced distant metastasis with no new safety issues. The companies plan regulatory discussions and potential accelerated approval submissions, with data presentations at upcoming medical meetings and continued follow-up for overall survival.

301 sources

Finance

Australian Oilseeds Short-Interest Rises 118.4% in July

July saw sharp increases in short interest for Australian Oilseeds, IM Cannabis, and Cannabis Global, while GrowHub and Croghan Bancshares experienced substantial declines or unusual changes in short interest. Notably, Australian Oilseeds jumped 118.4% to 136,664 shares and IM Cannabis rose 121.6% to 474,364 shares, with Cannabis Global expanding from zero to a large position, while GrowHub fell 57.8% to 153,743 shares and Croghan Bancshares climbed from zero to 55 shares due to reporting quirks.

415 sources

Photo: BugWarp / Wikimedia Commons (CC BY-SA 4.0)

Tech

SATA Plans Dividend; Ex-Dividend Date Set

Analysts see Satellogic offering greater upside than L3Harris but with higher volatility, while L3Harris is favored for steadier returns and institutional support. SATA Technology announced a dividend of 0.0516 per share and saw a director purchase of 15,900 shares, signaling confidence despite a modest payout and date discrepancies in notices.

6 sources